Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

CVS shares rose 4.7% at 3:43 p.m. in New York on Thursday, while Lilly fell 11%. Novo shares gained 2.1% in Copenhagen. Novo and Lilly have been locked in a fierce competition to dominate the ...

Summary. Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly’s obesity drug Zepbound from its standard commercial formularies starting July 1, 2025.

CVS Health opts for Wegovy and Saxenda on its formulary; ... Patients taking Zepbound will be able to switch to Wegovy if the Lilly drug is excluded from their coverage, Whitrap said.

Several major U.S. health insurers announce they will voluntarily speed up and simplify the prior authorization process.

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...

Eli Lilly’s stock wobbled after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda will become the preferred options ...

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...